CN1250374A - Therapeutic combination of mineral and vitamin in units of liquid preparation for oral administration - Google Patents
Therapeutic combination of mineral and vitamin in units of liquid preparation for oral administration Download PDFInfo
- Publication number
- CN1250374A CN1250374A CN98803347A CN98803347A CN1250374A CN 1250374 A CN1250374 A CN 1250374A CN 98803347 A CN98803347 A CN 98803347A CN 98803347 A CN98803347 A CN 98803347A CN 1250374 A CN1250374 A CN 1250374A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- compositions
- calcium
- salt
- gum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Abstract
The invention concerns a combination for preventing or treating osteoporosis in an aged subject, comprising as combined active principles metallic calcium and at least one vitamin D. The invention is characterised in that it comprises: a calcium salt dispersed in an liquid aqueous medium, said salt being substantially non-soluble in the liquid aqueous medium; at least one vitamin D; an agent for dissolving the vitamin D in the aqueous medium; and a gelling agent, for increasing the viscosity of the aqueous medium and maintaining the non-soluble calcium salt in homogeneous suspension in this aqueous medium.
Description
The present invention relates to comprise therapeutic combination as the minerals and vitamins of the calcium constituent of combined activity composition and at least one vitamin D.
The therapeutic effect that makes middle-older patient take calcium and vitamin D simultaneously to be produced is well-known, paper " the middle aged and aged women Hip Fracture being carried out 3 years effects after the treatment " (Effect of Calium and cholecalciferol Treatment for Three Years on HipFractures of Elderly Women) as Marie C.Chapuy etc. with calcium and cholecalciferol, British Medical Journal, 308,1081-1082 (April 23,1994); " vitamin D3 and calcium are to the control of middle aged and aged women Hip Fracture " (Vitamin D3and Calciumto Prevent Hip Fractures in Elderly Women), New England Journal of Medicine, 327,1637-1642 (December 3,1992); " vitamin D Can 3 and calcium are to the control of middle aged and aged women Hip Fracture " (Supplementation with Vitamin D3 and Calcium Prevent Hip Fractures inElderly Women), Nutrition Review, Vol.51,6, pp.183-185 is described.When these papers had also disclosed optimal dose every day with about 1000～1200mg calcium constituent and 800UI vitamin D3 and are used for prevention and treatment osteoporosis, the therapeutic alliance effect changed as the function of calcium and vitamin D dosage.
The known galenical preparation that much comprises calcium and vitamin D.
Put down in writing such Galenic unit's tablet form combination among the WO-A-96/09036 (Laboratoire Innothera), especially ground the tablet into powder, the absolute dosages of its calcium and vitamin D and relative dosage are as mentioned above described in the document.Take two tablets of tablets that ground into powder every day, can obtain required dosage every day of calcium and vitamin D.
(lamination tablet, coated tablet, buccal tablet or chewable tablet, effervescent granule, powder capsule etc.) also can be made into liquid dosage form except the dried dosage form of calcium/vitamin D compositions, for example, ampoule with its drinkable solution of comprising soluble calcium salt (gluconate or lactate) of packing into, because the dissolved result of calcium salt, such solution has certain acidity, can suppress the absorption of main constituent, and, can not be tolerated well by the patient.
Also can be made into the vitamin/calcium feed additive that comprises calcium and a kind of vitamin D and other compositions, for example, WO-A-96/31130 (Abbott Laboratories) put down in writing a kind of can be by the solid concentrates of water or fruit juice dilution.But, also to mention here, calcium salt exists with solvable or solubilized forms and causes low pH to cause above-mentioned inconvenience.
One of purpose of the present invention provides a kind of compositions that comprises the minerals and vitamins of calcium and vitamin D, and said composition exists with drinkable liquid unit formulation, and no strong acidity the patient can be tolerated well, and the absorption of active component is good.
It should be noted that above-mentioned " drinkable liquid unit formulation " is meant the liquid preparation of being convenient to drink, for example, what need not that the patient handles is contained in drinkable liquid preparation in sachet, medicine bottle or the ampoule, also comprises effervescent granule or soluble powder.
Another object of the present invention provides a kind of preparation, and its unit dose is equivalent to dosage every day (every day about 1000～1200mg calcium constituent and 800UI vitamin D) in the above-mentioned scope, owing to take 1 time and get final product every day, institute is so that treatment becomes easier.In fact, utilize the dried dosage form of mentioning among the above WO-A-96/09036 to be difficult to reach take every day and be less than two, and the tablet of compression feels too hard and fresh inadequately when oral in proportion, easily abandoned by the patient, but if drinkable liquid preparation, just analogue can not occur, every kind of composition can both be taken with bigger amount without difficulty.
A further object of the invention provides the drinkable liquid dosage form of the calcium/vitamin D compositions of suitable relative dosage with calcium and vitamin, and this dosage form can be used for preventing and treating the osteoporosis of mentioning when this description begins.
In fact we can say that the drinkable liquid unit formulation of known calcium/vitamin D compositions reckons without the desirable optimal proportion of mentioning in the above-mentioned document that is used to prevent and treat osteoporosis.In fact, these compositionss (for example, prevention rickets or osteomalacia are with vitamin D of booster dose) on other indications have general description.Perhaps, as vitamin/calcium tonic (food additive or OTC (over-the-counter) are sold " OTC " medicine), rather than the real medicine (content of vitamin D is relatively low when avoiding excessive use, the dangerous situation that occurs because of the inherent toxicity of this active component) of therapeutic purposes arranged.
For this reason, the invention provides a kind of drinkable liquid unit formulation of therapeutic combination of minerals and vitamins that is used in particular for preventing and treats the osteoporosis of middle-older patient, said composition comprises as the calcium constituent of combined activity composition and at least one vitamin D, it is characterized in that comprising the calcium salt that is dispersed in the water-based liquid medium, but this salt is insoluble to the aqueous liquid medium in fact; At least one vitamin D; The solubilizer of vitamin D in aqueous medium; And thereby the viscosity that is used for increasing aqueous medium makes insoluble calcium phosphate be present in gellant in the above-mentioned medium with the form of symmetric suspension.
According to various favorable characteristics:
The content of calcium constituent and vitamin D than (in Ca element mg/ vitamin D UI) in 1.0～1.5 scope, preferably in 1.2～1.3 scope,
Said composition is packaged into the dosage form of unit dose every day, and every dose comprises 800～1200mg calcium constituent and 600～1000UI vitamin D,
Insoluble calcium phosphate is a calcium carbonate,
It is that vitamin D2, vitamin D3 are cholecalciferol that vitamin D is selected from vitamin D2, or their mixture,
The solubilizer of vitamin D is selected from ethers, glycerol and saturated or unsaturated polyalkylene glycol glyceride, liquid fructose type saccharide, liquid 4-O-alpha-D-Glucopyranosyl-D-gluconic acid, polyglycolic acid sorbitan ester, hydrogenation or the non-hydrogenation polyoxyethylene castor oil and the maltodextrin of Polyethylene Glycol and ester thereof, propylene glycol, ethanol, diethylene glycol, wherein be preferably the polyglycolic acid sorbitan ester
Gellant is selected from natural gum such as guar gum, xanthan gum, tragacanth gum and arabic gum, agar, carboxymethyl starch sodium, the colloidal state anhydrous silica gel, cellulose derivative such as hydroxypropyl cellulose, sodium hydroxyethyl cellulose and carboxymethyl cellulose, acrylate copolymer, aluminium silicate and magnesium silicate, wherein be preferably xanthan gum
Also comprise antiseptic in the said composition, can be selected from sodio-derivative, benzoic acid and salt thereof, sorbic acid and salt thereof, bisulfites and the metabisulfite of P-hydroxybenzoic acid, its methyl ester and propyl ester, these esters,
Also comprise sweeting agent in the said composition, can be selected from aspartame, sucrose, potassiumacesulphame, saccharin sodium, sodium cyclamate and fructose,
The centesimal system prescription of said composition is as follows:
Calcium carbonate 16.67g
(be equivalent to calcium constituent: 6.67g)
Vitamin D
3(cholecalciferol) is in an amount equivalent to 5333.33UI
Polyglycolic acid sorbitan ester (Spheron MD 30/70) 0.05g
Xanthan gum 0.75g
Fructose 8.67g
Antiseptic q.s.
Aromatic q.s.
Pure water q.s.100ml
Final pH is between 7～9.Describe below and implement preferred (but non-limiting) embodiment of the present invention.
At first, the every kind of composition (being solubilizer, gellant, sweeting agent, antiseptic and the aromatic of vitamin D, insoluble calcium phosphate, vitamin D) in the prescription is specifically described.
1. vitamin D
This vitamin is a cholecalciferol (vitamin D
3, Roche produces), with oily solution (vegetable oil) form, every gram 100 ten thousand UI, or with granule form (100CWS
, Roche produces), every gram 100,000UI.All have the dl-alpha-tocopherol in the vitamin of above-mentioned two kinds of forms, this component has improved vitamins stability, and can prevent its oxidation.
2. insoluble calcium phosphate
As mentioned above, this salt must be insoluble in fact salt in prescription.It is present in the liquid medium with dispersive form, and the balance of salt can be not destroyed, therefore the character of this salt pref can not change (absorb better), and solution can acidify, and final pH is in 7～9 scope.
This insoluble calcium phosphate is the Scoralite of Scora production preferably
1B type calcium carbonate, it is a kind of white powder, and its superfine average diameter of particles is about 12 μ m, and density is higher, and (d is about 1.3g/m
3).
3. the solubilizer of vitamin D
Its effect is to make lipophilic vitamin (vitamin D3) compatible with hydrophilic environments, in other words, seek a kind of both can compatible with vitamin D3 (having that is to say that vitamin kept solubility and stability in this solvent) again can with the solvent or the cosolvent of the vitamin D3 of water compatible.
In addition, the taste of solubilizer should be able to be accepted by the patient, and can not influence the stability of selected gellant (seeing the following stated), also can the component in the liquid preparation not exerted an influence.
In meeting the various solubilizers of this standard, can give special heed to:
The laurate of Polyethylene Glycol (PEG), particularly PEG400 and their esters, particularly PEG200 and the stearate of PEG40,
The ethers of propylene glycol and diethylene glycol, particularly diethylene glycol monoethyl ether (Transcutol
),
Ethanol,
Glycerol, LARBRASOL (PEG-8 glycerol caprylate/decanoin (Labrasol particularly
) and unsaturated polyalkylene glycol glyceride (PEG-6 monoolein (Labrafil particularly
M1944CS)),
Saccharide, particularly liquid fructose and liquid 4-O-alpha-D-Glucopyranosyl-D-gluconic acid (Lycasin
80/55),
Polyglycolic acid sorbitan, particularly Spheron MD 30/70, this is present best solubilizer, the content of Spheron MD 30/70 in finished product preparation is 0.03wt%～0.05wt%, is preferably 0.05wt%,
Hydrogenation polyoxyethylene castor oil (Crodurel particularly
50, Cremophor
RH40) and non-hydrogenation polyoxyethylene castor oil (Etocas particularly
35HV),
Maltodextrin (Glucidex particularly
).
4. gellant
The effect of gellant is that calcium salt is present in the aqueous medium with the form of symmetric suspension, and solubilizer does not replace calcium salt.For this reason, with a kind of viscosity of polymer increase aqueous medium, this polymer possesses the structure that can make calcium carbonate disperse and keep dispersity, and, good mouthfeel and pleasant quality are arranged.
In various suitable gellant, can mention:
Natural gum, particularly guar gum, xanthan gum, tragacanth gum and arabic gum, present optimum selection is an xanthan gum, its content is preferably in about 0.75wt% in the scope of 0.1wt%～1.0wt%,
Agar,
Carboxymethyl starch sodium (Explotab particularly
),
Colloidal state anhydrous silica gel (Aerosil particularly
200),
Cellulose derivative, particularly hydroxypropyl cellulose (Klucel
), sodium hydroxyethyl cellulose (Natrosol
) and carboxymethyl cellulose (Blanose
),
Acrylate copolymer (Carbopol particularly
974P),
Aluminium silicate and magnesium silicate (Veegum particularly
HV).
5. sweeting agent
Selectable sweeting agent has many kinds, anyly can not influence enforcement of the present invention no matter select.
To should be mentioned that aspartame, sucrose, potassium acesulphame (Sunel especially
), saccharin sodium, sodium cyclamate and fructose (Fructofin
C type A12 1), preferably select fructose, it is a kind of natural sweetener, does not contain sucrose, can not produce taboo to non-insulin-dependent diabetes mellitus patient.
6. antiseptic
Selectable antiseptic has many kinds, anyly can not influence enforcement of the present invention no matter select, for example, sodio-derivative, benzoic acid and salt thereof, sorbic acid and the salt thereof of P-hydroxybenzoic acid, its methyl ester and propyl ester, these esters (particularly potassium sorbate), bisulfites and metabisulfite.
7. aromatic
Can select traditional additive to make preparation have needed taste (as Fructus Citri Limoniae, Fructus Citri tangerinae etc.).
Embodiment when being prepared is as follows:
In solubilizer, make the vitamin D3 solubilising,
In this solution impouring water, mix,
The stirring and dissolving antiseptic,
The stirring and dissolving sweeting agent,
Stirring adds aromatic (liquid) down,
The dispersed with stirring calcium carbonate,
The dispersed with stirring gellant,
Packing.
General formulation following (centesimal system prescription) preferably:
Calcium carbonate 16.67g
(be equivalent to calcium constituent: 6.67g)
Vitamin D
3(cholecalciferol) is in an amount equivalent to 5333.33UI
Polyglycolic acid sorbitan ester (Spheron MD 30/70) 0.05g
Xanthan gum 0.75g
Fructose 8.67g
Antiseptic q.s.
Aromatic q.s.
Pure water q.s.100ml
The pH of gained preparation is (no acidic) in 7～9 scope, its viscosities il=2000mPa.s ± 20%.
As change, available PEG400 (1g), propylene glycol (1g), Transcutol
(0.5g), ethanol (10g), glycerol (3g), liquid 4-O-alpha-D-Glucopyranosyl-D-gluconic acid (1g) or hydrogenation polyoxyethylene castor oil (1g) replace the 0.05g Spheron MD 30/70.
Equally, available guar gum (1g), hydroxypropyl cellulose (1g), hydroxyethyl-cellulose (1g), Veegum
HV (5g), sodium carboxymethyl cellulose (1g), Carbopol
974P (0.3g) or agar (0.5g) replace the 0.75g xanthan gum.
Claims (11)
1. the drinkable liquid unit formulation of minerals and vitamins therapeutic combination, can prevent and treat the osteoporosis of middle-older patient, described compositions comprises as the calcium constituent of combined activity composition and at least one vitamin D, it is characterized in that, comprise the calcium salt that is dispersed in the water-based liquid medium, but this salt is insoluble to described water-based liquid medium in fact; At least one vitamin D; The solubilizer of vitamin D in aqueous medium; And thereby the viscosity that is used for increasing aqueous medium makes insoluble calcium phosphate be present in gellant in the described medium with the form of symmetric suspension.
2. compositions as claimed in claim 1, wherein the content of calcium constituent and vitamin D ratio is in Ca element mg/ vitamin D UI, in 1.0～1.5 scope.
3. compositions as claimed in claim 2, wherein the content of calcium constituent and vitamin D ratio is in Ca element mg/ vitamin D UI, in 1.2～1.3 scope.
4. compositions as claimed in claim 1, its feature also are, are packaged into unit dose formulations every day, and every dose comprises 800～1200mg calcium constituent and 600～1000UI vitamin D.
5. compositions as claimed in claim 1, insoluble calcium phosphate wherein are calcium carbonate.
6. it is that vitamin D2, vitamin D3 are cholecalciferol that compositions as claimed in claim 1, vitamin D wherein are selected from vitamin D2, or their mixture,
7. compositions as claimed in claim 1, the solubilizer of vitamin D wherein is selected from ethers, glycerol and saturated or unsaturated polyalkylene glycol glyceride, liquid fructose type saccharide, liquid 4-O-alpha-D-Glucopyranosyl-D-gluconic acid, polyglycolic acid sorbitan ester, hydrogenation or the non-hydrogenation polyoxyethylene castor oil and the maltodextrin of Polyethylene Glycol and ester thereof, propylene glycol, ethanol, diethylene glycol, wherein is preferably the polyglycolic acid sorbitan ester.
8. compositions as claimed in claim 1, gellant wherein is selected from natural gum such as guar gum, xanthan gum, tragacanth gum and arabic gum, agar, carboxymethyl starch sodium, the colloidal state anhydrous silica gel, cellulose derivative such as hydroxypropyl cellulose, sodium hydroxyethyl cellulose and carboxymethyl cellulose, acrylate copolymer, aluminium silicate and magnesium silicate wherein are preferably xanthan gum.
9. compositions as claimed in claim 1 wherein also comprises antiseptic, is selected from sodio-derivative, benzoic acid and salt thereof, sorbic acid and salt thereof, bisulfites and the metabisulfite of P-hydroxybenzoic acid, its methyl ester and propyl ester, these esters.
10. compositions as claimed in claim 1 wherein also comprises sweeting agent, is selected from aspartame, sucrose, potassium acesulphame, saccharin sodium, sodium cyclamate and fructose,
11. compositions as claimed in claim 1, its centesimal system prescription is as follows:
Calcium carbonate 16.67g
(be equivalent to calcium constituent: 6.67g)
Vitamin D
3(cholecalciferol) is in an amount equivalent to 5333.33UI
Polyglycolic acid sorbitan ester (Spheron MD 30/70) 0.05g
Xanthan gum 0.75g
Fructose 8.67g
Antiseptic q.s.
Aromatic q.s
Pure water q.s.100ml
Final pH is in 7～9 scope.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9703061A FR2760639B1 (en) | 1997-03-14 | 1997-03-14 | MINERALO-VITAMIN THERAPEUTIC ASSOCIATION IN THE FORM OF A UNITABLE ORAL LIQUID PREPARATION |
| FR97/03061 | 1997-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1250374A true CN1250374A (en) | 2000-04-12 |
Family
ID=9504760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98803347A Pending CN1250374A (en) | 1997-03-14 | 1998-03-04 | Therapeutic combination of mineral and vitamin in units of liquid preparation for oral administration |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0971719A1 (en) |
| JP (1) | JP2001521495A (en) |
| CN (1) | CN1250374A (en) |
| CA (1) | CA2283691A1 (en) |
| EA (1) | EA199900830A1 (en) |
| FR (1) | FR2760639B1 (en) |
| WO (1) | WO1998041217A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102232967A (en) * | 2010-04-21 | 2011-11-09 | 武汉同济现代医药有限公司 | Novel oral effervescent agent for calcium supply and preparation method thereof |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITFI970184A1 (en) * | 1997-07-30 | 1999-01-30 | Menarini Farma Ind | PHARMACEUTICAL COMPOSITIONS CONTAINING VITAMIN D AND CALCIUM, THEIR PREPARATION AND THERAPEUTIC USE |
| DE102004051879A1 (en) * | 2004-10-26 | 2006-04-27 | Bayerl, Wolfgang P., Dr. | Curing agent, useful e.g. for the prophylaxis and therapy of osteoporosis, as food auxiliary agent intended to stimulate bone formation, comprises a combination of silicon dioxide with natural minerals and vitamin D |
| GB0507167D0 (en) * | 2005-04-08 | 2005-05-18 | Glaxosmithkline Consumer Healt | Composition |
| ES2567595T3 (en) * | 2005-10-12 | 2016-04-25 | Opko Renal, Llc | Methods and articles to treat the insufficiency and deficiency of 25-hydroxyvitamin D |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| HRP20211377T1 (en) | 2011-11-23 | 2022-01-07 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| RU2016143081A (en) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | NATURAL COMBINED HORMONE SUBSTITUTION COMPOSITIONS AND THERAPIES |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1062389B (en) * | 1958-02-11 | 1959-07-30 | Wander Ag Dr A | Process for the preparation of sterile vitamin D solutions containing calcium salts |
| US4737375A (en) * | 1985-12-26 | 1988-04-12 | The Procter & Gamble Company | Beverages and beverage concentrates nutritionally supplemented with calcium |
| GB8622025D0 (en) * | 1986-09-12 | 1986-10-22 | Beecham Group Plc | Composition |
| DK159807C (en) * | 1989-02-27 | 1992-06-29 | Gunnar Kjems | APPLICATION OF CALCIUM-SUSTAINABLE EMULSIONS FOR THE PREPARATION OF ORAL AGENTS FOR PREVENTION OR TREATMENT OF CALCIUM LACK OF Cattle, especially by calving fever |
| JP3708115B2 (en) * | 1991-05-06 | 2005-10-19 | ザ プロクター アンド ギャンブル カンパニー | Mixed calcium and vitamin D supplements |
| FR2724844B1 (en) * | 1994-09-23 | 1997-01-24 | Innothera Lab Sa | VITAMIN-CALCIUM THERAPEUTIC COMBINATION, PROCESS FOR OBTAINING SAME AND USE THEREOF |
| NZ306211A (en) * | 1995-04-07 | 1998-08-26 | Abbott Lab | Calcium supplements, in particular beverage concentrates, with vitamin d and a calcium source |
-
1997
- 1997-03-14 FR FR9703061A patent/FR2760639B1/en not_active Expired - Fee Related
-
1998
- 1998-03-04 CA CA002283691A patent/CA2283691A1/en not_active Abandoned
- 1998-03-04 EP EP98913826A patent/EP0971719A1/en not_active Withdrawn
- 1998-03-04 JP JP54018498A patent/JP2001521495A/en active Pending
- 1998-03-04 WO PCT/FR1998/000425 patent/WO1998041217A1/en not_active Application Discontinuation
- 1998-03-04 CN CN98803347A patent/CN1250374A/en active Pending
- 1998-03-04 EA EA199900830A patent/EA199900830A1/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102232967A (en) * | 2010-04-21 | 2011-11-09 | 武汉同济现代医药有限公司 | Novel oral effervescent agent for calcium supply and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2760639A1 (en) | 1998-09-18 |
| JP2001521495A (en) | 2001-11-06 |
| FR2760639B1 (en) | 2000-09-22 |
| WO1998041217A1 (en) | 1998-09-24 |
| EA199900830A1 (en) | 2000-04-24 |
| EP0971719A1 (en) | 2000-01-19 |
| CA2283691A1 (en) | 1998-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4969763B2 (en) | Ingestible composition containing odorous oil | |
| CN1250374A (en) | Therapeutic combination of mineral and vitamin in units of liquid preparation for oral administration | |
| CN1079672C (en) | Oral liquid alendronate formulations | |
| US4965252A (en) | Cholesterol-lowering combination compositions of guar gum and niacin | |
| CN1138535C (en) | Pharmacetical compositions contg. effervescent acid-base couple | |
| CA2200568C (en) | Therapeutic vitamin-calcium combination in unitary galenic tablet form, method for preparing same and use thereof | |
| JP2001527518A (en) | Suppression of undesirable taste in oral compositions | |
| JP2003055203A5 (en) | ||
| US5296241A (en) | Therapeutic composition and method of using same for treatment of hangover | |
| US5922351A (en) | Lubricants for use in tabletting | |
| CN101400270A (en) | Compositions for food or beverage with improved hygroscopicity | |
| CN1248681C (en) | Solid orally-dispersible pharmaceutical formulation | |
| EP1684732A2 (en) | Ibuprofen-containing soft gelatin capsules | |
| WO2007107787A2 (en) | Liquid and solid dosage formulations containing date fruit (phoenix dactylifera) | |
| AU679796B2 (en) | Antacid pharmaceutical composition | |
| CN1190185C (en) | Drinkable ibuprofen pharmaceutical suspension | |
| CN1686143A (en) | Hendecanoic acid testosterone self emulsified soft capsule composition and its preparation method | |
| CN1341016A (en) | Effervescent laxatives | |
| CN100335045C (en) | Preventive agent for ascites in poultry | |
| US11241408B2 (en) | Omega-3 compositions and methods relating thereto | |
| CN1170541C (en) | Oral liquid formulations of benzoxazinones HIV reverse transcriptase inhibitors | |
| CN1445349A (en) | Oil with conjugation linoleic acid added and method for slowing up oxidation of unsaturated fatty acid and promoting its absorption | |
| CN1149999C (en) | Pharmaceutical composition containing vitamin D and calcium, their preparation and therapeutic use | |
| JPH07206689A (en) | Curing composition and use of this composition for curing crapulence | |
| CN112741841A (en) | Three-dimensional calcium self-emulsifying effervescent composition and preparation method of preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |